Primary biliary cirrhosis

QJM: An International Journal of Medicine

Volumn 89, Issue 1, 1996, Pages 5-13

  O'Donohue, J ^a   Williams, R ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COLCHICINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MITOCHONDRION ANTIBODY; URSODEOXYCHOLIC ACID;

BIOCHEMISTRY; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ESCHERICHIA COLI; HISTOLOGY; HUMAN; LIVER TRANSPLANTATION; MYCOBACTERIUM; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; REVIEW; SURVIVAL; SYMPTOM; T LYMPHOCYTE;

EID: 0030046104     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.qjmed.a030137     Document Type: Review

References (78)

1. Lucey MR, Neuberger J, Williams R. Primary biliary cirrhosis in men. Gut 1986; 27:1373-6.
2. Myszor M, James OFW. The epidemiology of primary biliary cirrhosis in north-east England: an increasingly common disease. Q J Med 1990; 75:377-85.
3. Triger DR. Epidemiology: is there an environmental contribution? Presented at the International Association for the Study of the Liver, Brighton, England, 1992.
4. Watson RGP, Goss B, Angus PW, et al. Low prevalence of primary biliary cirrhosis in Victoria, Australia. Proceedings, International Association for the Study of the Liver, Brighton, 1992.
5. Hamlyn AN, Macklon AF, James O. Primary biliary cirrhosis: geographical clustering and symptomatic onset and seasonality. Gut 1983; 24:940-5.
6. Danielson A, Boqvist L, Uddenfeldt P, et al. Epidemiology of primary biliary cirrhosis in a defined rural population in the northern part of Sweden. Hepatology 1990; 11:458-64.
7. Witt-Sullivan H, Heathcote J, Cauch K, et al. The demography of primary biliary cirrhosis in Ontario, Canada. Hepatology 1990; 12:98-105.
8. Triger DR. Primary biliary cirrhosis: an epidemiological study. Br Med J 1980; 281:772-5.
9. Bach N, Schaffner F. Familial primary biliary cirrhosis. J Hepatol 1994; 20:698-701.
10. Brind A, Bray G, Portmann B, Williams R. Prevalence and pattern of familial disease in primary biliary cirrhosis. Gut 1995; 36:615-17.
11. Portmann B, Popper H, Neuberger J, Williams R. Sequential and diagnostic features in primary biliary cirrhosis bases on serial histological study in 209 patients. Gastroenterology 1985; 88:1777-90.
12. Alker JG, Doniach D, Roitt IM, et al. Serological tests in the diagnosis of primary biliary cirrhosis. Lancet 1965; 1:827-31.
13. Berg PA, Klein R, Lindenborn-Fotinos J. Antimitochondrial antibodies in primary biliary cirrhosis. J Hepatol 1986; 2:123-31.
14. Van der Water J, Gershwin ME, Leung P, Coppel RL. The autoepitope of the 74 kDa mitochondrial autoantigen of primary biliary cirrhosis corresponds to the functional site of the dihydrolipoamide acetyltransferase. J Exp Med 1988; 167:1791-99.
15. Fussey SP, Guest JR, James OF, Bassendine MF, Yeaman SJ. Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. Proc Natl Acad Sci USA 1988; 85:8654-8.
16. Bassendine EMF, Yeaman SJ. Serological markers of primary biliary cirrhosis: diagnosis, prognosis and subsets. Hepatology 1992; 15:545-7.
17. Krams SM, Surh C, Coppel R, et al. Immunisation of experimental animals with dihydrolipoamide acetyltransferase as a purified recombinant polypeptide generates antimitochondrial antibodies but not primary biliary cirrhosis. Hepatology 1987; 9:414-16.
18. Van de Water J, Turchany J, Leung PS, et al Molecular mimicry in primary biliary cirrhosis. J Clin Invest 1993; 91:2653-64.
19. Joplin R, Lindsay JG, Johnson GD, Strain A, Neuberger J. Membrane dihydrolipoamide acetyltransferase (E2) on human biliary epithelial cells in primary biliary cirrhosis. Lancet 1992; 339:93-4.
20. Tsuneyama K, Van de Water J, Nakanuma Y, et al. Human combinatorial antibodies and mouse monoclonal antibodies to PCD-E2 produce abnormal apical staining of salivary glands in patients with coexistent primary biliary cirrhosis and Sogren's syndrome. Hepatology 1994; 20:893-8.
21. Joplin R, Johnson G, Matthews JB, et al. Distribution of pyruvate dehydrogenase dihydrolipoamide acetyltransferase (PDC-E2) and another mitochondrial marker in salivary gland and biliary epithelium from patients with primary biliary cirrhosis. Hepatohgy 1994; 20:1375-80.
22. Fiezi T. Immunoglobulins in chronic liver disease. Gut 1968; 9:193-8.
23. Donaldson P, Doherty D, Underhill J, Williams R. The molecular genetics of autoimmune liver disease. Hepatology 1994; 20:225-39.
24. Ballardini C, Mirakian R, Bianchi FB, Pisi E, Doniach D, Bottazzo GF. Aberrant expression of HLA-DR antigens on bile duct epithelium in primary biliary cirrhosis. Lancet 1984; 2:1009-13.
25. Adams DH, Hubscher SC, Shaw J, Johnson CD, Babbs L, Rothlein R, Neuberger J. Increased expression of ICAM-1 on bile ducts in primary biliary cirrhosis and sclerosing cholangitis. Hepatohgy 1991; 14:426-431.
26. Lim AG, Jazrawi RP, Ahmed HA, Levy JH, Zuin M, Douds AC, Maxwell JD, Northfield TC. Soluble intercellular adhesion molecule-1 in primary biliary cirrhosis: relationship with disease stage, immune activity and cholestasis. Hepatology 1994; 20:882-8.
27. Jones DEJ, Gregory WL, Bassendin MF. Primary biliary cirrhosis. In: Thomas H, ed. Immunology and liver disease. London, Kluwer, 1993:121-41.
28. Ohmoto M, Yamamoto K, Kobashi H, et al. Multiple T-cell clones in the liver of primary biliary cirrhosis: polymerase chain reaction and single-strand conformational polymorhism analysis of TCR Vβ. Hepatology 1994; 20(4): 149A.
29. Martinez OM, Villanueva JC, Gershwin E, Krams SM. Cytokine patterns and cytotoxic mediators in primary biliary cirrhosis. Hepatology 1995; 21:113-19.
30. Jones DEJ, Palmer JM, James OFW, Yeaman SJ, Bassendine MF, Diamond AG. T-cell responses to the components of pyruvate dehydrogenase complex in primary biliary cirrhosis. Hepatology 1995; 21:995-1002.
31. Burroughs A, Rosenstein IJ, Epstein O, Hamilton-Miller JMT, Brumfitt W, Sherlock S. Bacteriuria and primary biliary cirrhosis. Gut 1984; 25:133-7.
32. Hopf U, Moller B, Stemerowicz R, Lobeck H, Rodloff A, Freudenberg M, Calanos C, Huhn D. Relation between Escherichia Coli R (rough) forms in gut, lipid A in liver, and primary biliary cirrhosis. Lancet 1989; 2:1419-22.
33. Butler PP, Valle F, Hamilton-Miller JMT, Brumfitt W, Baum H, Burroughs A M2 mitochondrial antibodies and urinary rough mutant bacteria in patients with primary biliary cirrhosis and in patients with recurrent bacteriuria. J Hepatol 1993; 17:408-14.
34. Burroughs AK, Sternberg MJE, Baum H. Molecular mimicry in liver disease. Nature 1992; 358:377-8.
35. Tsuneyama K, Van de Water J, Leung SC, et al. Abnormal expression of PDC-E2 on the luminal surface of biliary epithelium occurs before MHC class II and BB1/B7 expression. Hepatology 1994; 20(4):148A.
36. Floreani A, Bassendine MF, Mitchison H, Freeman R, James OFW. No specific association between primary biliary cirrhosis and bacteriuria. J Hepatol 1989; 8:201-7.
37. Vilagut L, Vila J, Vinas O, Pares A, Gines AM, Jimenez de Anta MT, Rodes J. Cross-reactivity of anti-Mycobacterium gordonae antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis. J Hepatol 1994; 21:673-7.
38. Vilagut L, Villa J, Pares A, Vinas O, Gines A, Bruguera M, Jimenez de Anta MT, Rodes J. Mycobacterium gordonae DNA in liver tissue of patients with primary biliary cirrhosis. J Hepatol 1994; 21:S87.
39. O'Donohue J, McFarlane B, Bomford A, Yates M, Williams R. Antibodies to atypical mycobacteria in primary biliary cirrhosis. J Hepatol 1994; 21:887-9.
40. Crowe J, Christensen E, Doniach D, Popper H, Tygstrup N, Williams R. Presentation of PBC. Am J Gastroenterol 1985; 80:466-8.
41. Christensen E, Crowe J, Doniach D, et al. Clinical patterns and course of disease in primary biliary cirrhosis. Castroenterology 1980; 78:236-47.
42. Sherlock S. Primary biliary cirrhosis: definition and epidemiologicaf features. Immunology and liver. Falk Symposium 1992; 70:341-9.
43. Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 1994; 20:707-13.
44. Mitchison HC, Lucey MR, Kelly PJ, Neuberger JM, Williams R, James OFW. Symptom development and prognosis in primary biliary cirrhosis: a study in two centres. Gastroenterology 1990; 99:778-84.
45. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10:1-7.
46. Christensen E, Neuberger J, Crowe J, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology 1985; 89:1084-91.
47. Michieletti P, Wanless IR, Katz A, Scheuer PJ, Yeaman SJ, Bassendine MF, Palmer JM. Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune hepatitis. Gut 1994; 35:260-5.
48. Ben-Ari Z, Dhillon AP, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology 1993; 18:10-15.
49. Colombata LA, Alvarez F, Cole J, Huet P-M. Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis? Gastroenterology 1994; 107:1839-43.
50. Sherlock S. Primary biliary cirrhosis: clarifying the issues. Am J Med 1994; 96(1A):27S-33S.
51. Meys E, Fontanges E, Fourcade N, Thomasson A, Pouyet M, Delmas PD. Bone loss after orthoptic liver transplantation. Am J Med 1994; 97:445-50.
52. Rosen H. Primary biliary cirrhosis and bone disease. Hepatology 1995; 21:253-5.
53. Camisasca M, Crosignana A, Battezzati PM, Aslbisetti W, Grandinetti G, Pietrogrande L, Biffi A, et al. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology 1994; 20:633-7.
54. Lombard M, Portmann B, Neuberger J, et al. Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology 1993; 104:519-26.
55. Bergasa NV, Ailing D, Talbot T, et al. Naloxone ameliorates the pruritus of cholestasis: results of a double-blind randomised placebo-controlled trial. Hepatology 1992; 16:152A.
56. Raderer M, Muller C, Scheithauer W. Ondensetron for pruritus of cholestasis. N Engl J Med 1994; 330:1540.
57. Yurner IB, Rawlins MD, Wood P, James OF. Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis. Aliment Pharmacol Ther 1994; 8:337-42.
58. Goddard CJR, Warnes TW. Primary biliary cirrhosis: how should we evaluate new treatments? Lancet 1994; 343:1305-6.
59. Heathcote J, Ross A, Sherlock S. A prospective controlled trial of azathioprine in primary biliary cirrhosis. Gastroenterology 1976; 70:656-60.
60. Christensen E, Neuberger J, Crowe J, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis: final results of an international trial. Gastroenterology 1985; 89:1084-91.
61. Mitchison HC, Bassendine MF, Malcolm AJ, et al. A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss. Hepatology 1989; 10:420-9.
62. Kaplan MM, Knox TA. Treatment of primary biliary cirrhosis with weekly low-dose methotrexate. Gastroenterology 1991; 101:1332-8.
63. Kaplan MM, Alling DW, Zimmerman HJ, et al. A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med 1986; 315:1448-54.
64. Warnes TW, Smith A, Lee F, et al. A controlled trial or colchicine in primary biliary cirrhosis: trial design and preliminary report. J Hepatol 1987; 5:1-7.
65. Hoofnagle J, David GL, Schnafer D, et al. Randomised trial of chlorambucil for primary biliary cirrhosis. Gastroenterology 1986; 91:1327-34.
66. Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106:1284-90.
67. Combes B, Carithers RL, Maddrey WC, Munoz SJ, McDonald MF, Garcia-Tsao G, et al. A randomised, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995; 22:759-66.
68. Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian multicenter double-blind randomised controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 10:1149-56.
69. Poupon RE, Poupon R, Balkau B and the UDCA-PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994; 330:1342-7.
70. Lim AG, Northfield TC. Ursodeoxycholic acid and primary biliary cirrhosis. Br Med J 1994; 309:491-2.
71. Sherlock S. Therapeutic trials in primary biliary cirrhosis. Q J Med 1994; 87:701-3.
72. Jones DE, James OFW, Bassendine MF. Ursodeoxycholic acid therapy in primary biliary cirrhosis. Hepatology 1995; 21:1469-73.
73. Heathcote EJ, Lindor KD, Poupon R, et al. Combined analysis of French, American and Canadian randomised controlled triais of ursodeoxycholic acid therapy in primary biliary cirrhosis. Gastroenterology 1995; 108:1082(A).
74. Lindor KD. Colchicine and ursodeoxycholic acid for primary biliary cirrhosis: emerging results. Gastroenterology 1995; 108:1592-3.
75. Lindor KD, Jorgensen RA, Anderson ML, et al. The combination of ursodeoxycholic acid (UDCA) and methotrexate (MTX) for primary biliary cirrhosis (PBC): the results of a pilot study. Hepatology 1994; 20:202(A).
76. Wolfhagen FHJ, van Buuren HR, Schakm SW. Combined treatment with ursodeoxycholic acid and prednisolone in primary biliary cirrhosis. Neth J Med 1994; 44:84-90.
77. Hubscher SG, Elias E, Buckels JAC, Mayer D, McMaster P, Neuberger JM. Primary biliary cirrhosis: histological evidence of disease recurrence after liver transplantation. J Hepatol 1993; 18:173-84.
78. Balan V, Batts K, Porayko MK, Krom RAF, Ludwig J, Wiesner RH. Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation. Hepatology 1993; 18:1392-8.